NCT02516241 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT02516241
Title	Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	AstraZeneca
Indications	bladder urothelial carcinoma renal pelvis transitional cell carcinoma ureter transitional cell carcinoma urethra transitional cell carcinoma transitional cell carcinoma
Therapies	Durvalumab + Tremelimumab Carboplatin + Cisplatin + Gemcitabine Durvalumab
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| NLD \| ITA \| ISR \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BRA \| BEL \| AUT \| AUS

No variant requirements are available.